From the Wires
Atossa Genetics to Present at the 15th Annual BIO CEO and Investor Conference
Presentation to Be Webcast at 1:00 pm ET on February 11, 2013
Jan. 28, 2013 08:15 AM
SEATTLE, WA -- (Marketwire) -- 01/28/13 -- Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President, will present the Company's products and services at the 15th Annual BIO CEO and Investor Conference at the Waldorf Astoria Hotel in New York City, on Monday, February 11, 2013, at 1:00 pm Eastern Time (10:00 am Pacific Time). Dr. Quay's presentation will be webcast via the Company's website at www.atossagenetics.com.
Dr. Quay stated, "The national launch of our ForeCYTE Breast Health Test is an important achievement that positions Atossa for accelerated growth in 2013 and beyond. I look forward to presenting our business model, marketing plan, and additional products and laboratory services to institutional investors at this premier event. I believe the 2013 U.S. rollout of our ForeCYTE and ArgusCYTE Breast Health Test, launch of the FullCYTE Breast Health Test and NextCYTE Breast Health Test, and initiation of clinical trials for our intraductal therapy, represent significant upside potential for investors this year."
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
About Marketwire .Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
.gif)
The saying “if it doesn’t exist on the Internet, it doesn’t exist”[1] is ringing truer every day. Nowadays, it is hard to imagine most businesses without an e-commerce platform, let alone without a web presence at all. Since e-commerce is becoming the new standard, e-commerce per...
In my recent article, "Five Steps to Improve E-Commerce Performance for Increased Sales: Introduction” I discussed problems encountered by our client TescaraHats (name changed for commercial reasons), a European market leader in manufacturing customized hats. The company quickly ...
Complexity is the new reality of web and mobile applications with almost no new release going out without the addition of services and applications spread across many different companies. But the reality of this new interrelationship is still the same: If a third-party Internet o...
Although I started with ColdFusion for application development, I did plenty brochureware sites with HTML. I believe the version was HTML 2.0 for IE 2.0. I lived in the browser world for years doing ColdFusion, ASP, and HTML sites. When winforms and Smart Client with web services...
Compuware Corporation has announced the convergence of dynaTrace PurePath® Technology and the Gomez Performance Network, creating a powerful User Experience Management (UEM) solution. Compuware now offers a APMaaS solution that provides a complete UEM offering, including real-use...
